Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade

Company Performance - Novo Nordisk's stock closed at $84.62, reflecting a -1.9% change from the previous day's closing price, underperforming the S&P 500's daily gain of 0.16% [1] - Over the past month, Novo Nordisk shares have decreased by 19.35%, which is significantly worse than the Medical sector's loss of 5.3% and the S&P 500's loss of 2.2% [1] Upcoming Earnings - Novo Nordisk is expected to report earnings of$ 0.85 per share, indicating a year-over-year growth of 19.72% [2] - The consensus estimate for revenue is projected at $11.34 billion, representing a 19.23% increase from the same quarter last year [2] Analyst Projections - Recent shifts in analyst projections for Novo Nordisk are important for investors, as positive changes often reflect optimism regarding the company's business and profitability [3] - The Zacks Consensus EPS estimate has decreased by 3.06% over the last 30 days, and Novo Nordisk currently holds a Zacks Rank of 4 (Sell) [5] Valuation Metrics - Novo Nordisk has a Forward P/E ratio of 22.2, which is a premium compared to the industry's average Forward P/E of 12.75 [6] - The company has a PEG ratio of 0.92, while the Large Cap Pharmaceuticals industry has an average PEG ratio of 1.28 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 187, placing it in the bottom 26% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]